person · Reporting owner
BIENAIME JEAN JACQUES
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ascendis Pharma A/SASND · Entity 1628 | Director | April 14, 2026 | September 28, 2026 |
| IMMUNIC, INC.VTL · Entity 6306 | Director | September 24, 2018 | September 24, 2018 |
| INCYTE CORPINCY · Entity 3182 | Director | June 08, 2026 | June 10, 2026 |
| Immunome Inc.IMNM · Entity 4219 | Director | June 10, 2026 | June 12, 2026 |
| Keros Therapeutics, Inc.KROS · Entity 6242 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ascendis Pharma A/S
Report date April 14, 2026 · Filed September 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $172.35 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2026-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-14 · Disposition to issuer · Disposed 9,160 · Balance 0 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $249.84 · Expires 2036-04-14 | Direct | 9,160 |
Reported balance
After 2026-04-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-14 · Grant · Acquired 9,160 · Balance 9,160 F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer. F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments. |
Filing footnotes · ownership attribution and instrument terms
F1: The warrants vest 25% on June 10, 2026 and thereafter in 36 equal monthly installments.
F2: The Reporting Person agreed to cancellation of a warrant granted on June 10, 2025, and was awarded a new warrant as part of his appointment to the board of directors of the issuer.
F3: The warrants vest 25% on April 14, 2027 and thereafter in 36 equal monthly installments.
IMMUNIC, INC.
Report date September 24, 2018 · Filed September 24, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,500 |
Reported balance
After 2018-09-24 transaction · row 1
1 source rowRow 1 · 2018-09-24 · Sale · Disposed 26,619 · Balance 18,500 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.30 to $0.3021. The reporting person undertakes to provide Vital Therapies, Inc., any security holder of Vital Therapies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price range set forth in this footnote (1) to this Form 4.
INCYTE CORP
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,424 |
Reported balance
After 2026-06-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 1,642 · Balance 24,424 F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
| Non Qualfied Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.64 · Expires 2036-06-07 | Direct | 6,111 |
Reported balance
After 2026-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-08 · Grant · Acquired 6,111 · Balance 6,111 F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan). |
Filing footnotes · ownership attribution and instrument terms
F1: This award of restricted stock units ("RSUs") vests in full on the first anniversary of the date of grant or, if earlier, the date of the next regular annual meeting of the Company's stockholders or upon a change of control (as defined in the RSU plan). The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including this grant, this includes an aggregate of 1,642 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F3: This option vests in full on the first anniversary of the date of grant, or if earlier, the date of the next regular annual meeting of the Company's stockholders or upon change of control (as defined in the option plan).
Immunome Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.16 · Expires 2036-06-09 | Direct | 9,897 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 9,897 · Balance 9,897 F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.
Keros Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,592 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Purchase · Acquired 1,000 · Balance 19,592 F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were purchased pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.02 to $10.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOMARIN PHARMACEUTICAL INC
Report date May 20, 2024 · Filed May 21, 2024
Section 16 reporting ended · disclosed 2024-05-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 473,792 |
Reported balance
After 2024-05-20 transaction · row 1
1 source rowRow 1 · 2024-05-20 · Tax withholding · Disposed 1,202 · Balance 473,792 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Jean-Jacques Bienaime Family Trust | 247,333 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 247,333 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 1 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 100 |
| Common StockSEC Table I · non-derivative | IndirectShares held as UTMA custodian for child 2 | 100 |
Reported balance
Holding disclosure · report date 2024-05-20 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 100 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 21,453 | $94.65 | $2,030,526.45 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,760 F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F6 · price: The price in column 4 is the weighted average price. The price actually received ranged from $94.12 to $95.11. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 10, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 30,000 | $67.81 | $2,034,300.00 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · derivative · entry 13 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,130 Underlying: Common Stock · 30,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F8 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 30,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · derivative · entry 12 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,130 Underlying: Common Stock · 30,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F8 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,410 | $95.90 | $135,219.00 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,213 F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F5 · price: The price in column 4 is the weighted average price. The price actually received ranged from $95.86 to $95.97. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 14,964 | $95.49 | $1,428,912.36 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 427,623 F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F4 · price: The price in column 4 is the weighted average price. The price actually received ranged from $94.86 to $95.85. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 13,626 | $94.22 | $1,283,841.72 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 442,587 F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F3 · price: The price in column 4 is the weighted average price. The price actually received ranged from $93.85 to $94.83. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 09, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 30,000 | $67.81 | $2,034,300.00 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 456,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| April 28, 2023 Filed May 11, 2023 21:04 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 317 | $66.88 | $21,200.96 |
DisclosureSEC source: 0001209191-23-028813 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 426,213 F1 · date: Represents the shares acquired by the reporting person on April 28, 2023, pursuant to the issuer's Employee Stock Purchase Plan. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-024073 · doc4.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,130 Underlying: Common Stock · 10,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 10,000 | $99.56 | $995,600.00 |
DisclosureSEC source: 0001209191-23-024073 · doc4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,896 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| April 10, 2023 Filed Apr 12, 2023 20:08 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $67.81 | $678,100.00 |
DisclosureSEC source: 0001209191-23-024073 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-023942 · doc4.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,130 Underlying: Common Stock · 10,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 10,000 | $96.13 | $961,300.00 |
DisclosureSEC source: 0001209191-23-023942 · doc4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 425,896 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 23:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $67.81 | $678,100.00 |
DisclosureSEC source: 0001209191-23-023942 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 435,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| March 16, 2023 Filed Mar 18, 2023 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 88,623 | $93.41 | $8,278,274.43 |
DisclosureSEC source: 0001567619-23-005285 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,896 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy Common Stock) · Derivative | 49,430 | $0.00 Strike: $87.74 | $0.00 |
DisclosureSEC source: 0001567619-23-005285 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,430 Underlying: Common Stock · 49,430 shares Expires 2033-03-14 F2 · derivative.exercise_date: Option grant vests 12/36th on March 15, 2024 and 1/36th on the 15th day of each month thereafter. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 9,437 | $87.74 | $828,002.38 |
DisclosureSEC source: 0001567619-23-005285 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,519 Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 01:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 36,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-005285 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 523,956 F1 · price: Restricted stock units granted on March 15, 2023. Price not applicable. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 23:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 8,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-005059 · doc1.xml · derivative · entry 9 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,130 Underlying: Common Stock · 8,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 23:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 8,000 | $90.45 | $723,600.00 |
DisclosureSEC source: 0001567619-23-005059 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,856 F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 23:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 8,000 | $67.81 | $542,480.00 |
DisclosureSEC source: 0001567619-23-005059 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 23:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-005059 · doc1.xml · derivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,130 Underlying: Common Stock · 15,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. F3 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 23:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $92.28 | $1,384,200.00 |
DisclosureSEC source: 0001567619-23-005059 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,856 F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 23:40 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $67.81 | $1,017,150.00 |
DisclosureSEC source: 0001567619-23-005059 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,856 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 32,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014601 · doc4.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 487,856 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F5 · shares: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 44,860 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014601 · doc4.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,884 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. F4 · shares: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 89,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014601 · doc4.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 410,024 F1 · date: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis. F2 · shares: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan. F3 · shares: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 6,000 | $109.15 | $654,900.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · nonDerivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,324 F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 6,000 | $67.81 | $406,860.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · nonDerivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 6,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · derivative · entry 9 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,130 Underlying: Common Stock · 6,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · derivative · entry 8 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,130 Underlying: Common Stock · 15,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 15,000 | $110.11 | $1,651,650.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,324 F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| February 10, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $67.81 | $1,017,150.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| February 09, 2023 Filed Feb 12, 2024 20:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000008 · wk-form5_1707769448.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,562 Read SEC document |
| February 07, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held as UTMA custodian for child Disclosed balance after: 100 F2 · kind: This transaction involved a gift of securities by the reporting person to his child under the Uniform Transfers to Minors Act. Read SEC document |
| February 07, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held as UTMA custodian for child Disclosed balance after: 100 F2 · kind: This transaction involved a gift of securities by the reporting person to his child under the Uniform Transfers to Minors Act. Read SEC document |
| February 07, 2023 Filed Feb 15, 2023 01:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 200 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-003004 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Shares held by Jean-Jacques Bienaime Family Trust Disclosed balance after: 247,333 F2 · kind: This transaction involved a gift of securities by the reporting person to his child under the Uniform Transfers to Minors Act. Read SEC document |
| February 07, 2023 Filed Feb 12, 2024 20:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000008 · wk-form5_1707769448.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,762 Read SEC document |
| February 06, 2023 Filed Feb 12, 2024 20:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000008 · wk-form5_1707769448.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,162 Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 02:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-001000 · doc1.xml · derivative · entry 7 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,130 Underlying: Common Stock · 10,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 02:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 10,000 | $111.55 | $1,115,500.00 |
DisclosureSEC source: 0001567619-23-001000 · doc1.xml · nonDerivative · entry 4 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,424 F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 02:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $67.81 | $678,100.00 |
DisclosureSEC source: 0001567619-23-001000 · doc1.xml · nonDerivative · entry 3 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · date: Trade made pursuant to a 10b5-1 plan executed on May 3, 2022. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 02:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 10,000 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001567619-23-001000 · doc1.xml · derivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,130 Underlying: Common Stock · 10,000 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F4 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 02:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 10,000 | $112.25 | $1,122,500.00 |
DisclosureSEC source: 0001567619-23-001000 · doc1.xml · nonDerivative · entry 2 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,424 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. F2 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 02:41 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 10,000 | $67.81 | $678,100.00 |
DisclosureSEC source: 0001567619-23-001000 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. Read SEC document |
| December 28, 2022 Filed Feb 14, 2023 01:01 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-002657 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,324 F1 · date: On December 28, 2022 the reporting person gifted 100 shares to an educational institution. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 21:43 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 1,000 | $106.89 | $106,890.00 |
DisclosureSEC source: 0001567619-22-021653 · doc1.xml · nonDerivative · entry 1 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,424 F1 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 69 | $104.06 | $7,179.80 |
DisclosureSEC source: 0001567619-22-021361 · doc1.xml · nonDerivative · entry 6 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,424 F1 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 02:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 100 | $104.00 | $10,400.00 |
DisclosureSEC source: 0001567619-22-021361 · doc1.xml · nonDerivative · entry 5 BIENAIME JEAN JACQUES · CIK 0001221590 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,493 F1 · date: The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 100 shares, with the reporting person's purchase of shares at a price of $86.1178 on November 2, 2022. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.